{"id":45955,"date":"2025-11-06T00:24:21","date_gmt":"2025-11-05T16:24:21","guid":{"rendered":"https:\/\/flcube.com\/?p=45955"},"modified":"2025-11-06T00:24:21","modified_gmt":"2025-11-05T16:24:21","slug":"sinotau-receives-fda-nda-approval-for-mk%e2%80%916240-tau-pet-imaging-agent","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45955","title":{"rendered":"Sinotau Receives FDA NDA Approval for MK\u20116240 Tau PET Imaging Agent"},"content":{"rendered":"\n<p>Beijing Sinotau International Pharmaceutical Technology Co.,\u202fLtd. announced today that the New Drug Application (NDA) for <strong>MK\u20116240\/XTR006<\/strong>, developed by its partner Lantheus Holdings, Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/LNTH:NASDAQ\">NASDAQ: LNTH<\/a>), has been accepted by the U.S. Food and Drug Administration (FDA). The agent is designed to detect tau neuro\u2011fibrillary tangle (NFT) pathology in patients with cognitive impairment who are being evaluated for Alzheimer\u2019s disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-acceptance-amp-timeline\">FDA Acceptance &amp; Timeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NDA Status<\/strong> \u2013 Full acceptance by the FDA, following prior Fast\u2011Track designation.<\/li>\n\n\n\n<li><strong>PDUFA Action Date<\/strong> \u2013 August\u202f13,\u202f2026, giving a clear regulatory runway.<\/li>\n\n\n\n<li><strong>Manufacturing Rights<\/strong> \u2013 Sinotau holds exclusive rights for development, production, and commercialization in China since 2017.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence\">Clinical Evidence<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202f3 Trials<\/strong> \u2013 Two pivotal studies in the U.S. confirmed high sensitivity and specificity for detecting tau NFTs in early Alzheimer\u2019s disease.<\/li>\n\n\n\n<li><strong>Co\u2011Primary Endpoints<\/strong> \u2013 Both sensitivity and specificity achieved the required thresholds, supporting diagnostic accuracy.<\/li>\n\n\n\n<li><strong>China Phase\u202f3<\/strong> \u2013 The agent is also active in a domestic Phase\u202f3 program, underscoring Sinotau\u2019s global\u2011local strategy.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Diagnostic Gap Fulfillment<\/strong> \u2013 MK\u20116240 offers a unique tau\u2011targeted PET imaging platform, addressing the unmet need for early Alzheimer\u2019s biomarkers.<\/li>\n\n\n\n<li><strong>Market Lead<\/strong> \u2013 A first\u2011in\u2011class product positions Sinotau and Lantheus as pioneers in neuroimaging diagnostics.<\/li>\n\n\n\n<li><strong>Commercial Opportunity<\/strong> \u2013 With exclusive Chinese rights and an FDA\u2011approved NDA, Sinotau can rapidly scale production and distribution once the PDUFA milestone is met.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-bottom-line\">Bottom Line<\/h2>\n\n\n\n<p>Sinotau\u2019s FDA NDA acceptance for MK\u20116240\/XTR006 marks a pivotal milestone for Alzheimer\u2019s diagnostics. The agent\u2019s proven clinical performance, combined with Sinotau\u2019s exclusive Chinese manufacturing and commercialization authority, positions the company\u2014and its Lantheus partner\u2014to capture a substantial share of the rapidly expanding dementia imaging market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Beijing Sinotau International Pharmaceutical Technology Co.,\u202fLtd. announced today that the New Drug Application (NDA) for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45958,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4434,38,4435,2045],"class_list":["post-45955","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-lantheus","tag-market-approval-filings","tag-nasdaq-lnth","tag-sinotau-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sinotau Receives FDA NDA Approval for MK\u20116240 Tau PET Imaging Agent - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing Sinotau International Pharmaceutical Technology Co.,\u202fLtd. announced today that the New Drug Application (NDA) for MK\u20116240\/XTR006, developed by its partner Lantheus Holdings, Inc. (NASDAQ: LNTH), has been accepted by the U.S. Food and Drug Administration (FDA). The agent is designed to detect tau neuro\u2011fibrillary tangle (NFT) pathology in patients with cognitive impairment who are being evaluated for Alzheimer\u2019s disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45955\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sinotau Receives FDA NDA Approval for MK\u20116240 Tau PET Imaging Agent\" \/>\n<meta property=\"og:description\" content=\"Beijing Sinotau International Pharmaceutical Technology Co.,\u202fLtd. announced today that the New Drug Application (NDA) for MK\u20116240\/XTR006, developed by its partner Lantheus Holdings, Inc. (NASDAQ: LNTH), has been accepted by the U.S. Food and Drug Administration (FDA). The agent is designed to detect tau neuro\u2011fibrillary tangle (NFT) pathology in patients with cognitive impairment who are being evaluated for Alzheimer\u2019s disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45955\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-05T16:24:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0513.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45955#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45955\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sinotau Receives FDA NDA Approval for MK\u20116240 Tau PET Imaging Agent\",\"datePublished\":\"2025-11-05T16:24:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45955\"},\"wordCount\":291,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45955#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0513.webp\",\"keywords\":[\"Lantheus\",\"Market approval filings\",\"NASDAQ: LNTH\",\"Sinotau Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45955#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45955\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45955\",\"name\":\"Sinotau Receives FDA NDA Approval for MK\u20116240 Tau PET Imaging Agent - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45955#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45955#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0513.webp\",\"datePublished\":\"2025-11-05T16:24:21+00:00\",\"description\":\"Beijing Sinotau International Pharmaceutical Technology Co.,\u202fLtd. announced today that the New Drug Application (NDA) for MK\u20116240\\\/XTR006, developed by its partner Lantheus Holdings, Inc. (NASDAQ: LNTH), has been accepted by the U.S. Food and Drug Administration (FDA). The agent is designed to detect tau neuro\u2011fibrillary tangle (NFT) pathology in patients with cognitive impairment who are being evaluated for Alzheimer\u2019s disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45955#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45955\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45955#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0513.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0513.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sinotau Receives FDA NDA Approval for MK\u20116240 Tau PET Imaging Agent\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45955#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sinotau Receives FDA NDA Approval for MK\u20116240 Tau PET Imaging Agent\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sinotau Receives FDA NDA Approval for MK\u20116240 Tau PET Imaging Agent - Insight, China&#039;s Pharmaceutical Industry","description":"Beijing Sinotau International Pharmaceutical Technology Co.,\u202fLtd. announced today that the New Drug Application (NDA) for MK\u20116240\/XTR006, developed by its partner Lantheus Holdings, Inc. (NASDAQ: LNTH), has been accepted by the U.S. Food and Drug Administration (FDA). The agent is designed to detect tau neuro\u2011fibrillary tangle (NFT) pathology in patients with cognitive impairment who are being evaluated for Alzheimer\u2019s disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45955","og_locale":"en_US","og_type":"article","og_title":"Sinotau Receives FDA NDA Approval for MK\u20116240 Tau PET Imaging Agent","og_description":"Beijing Sinotau International Pharmaceutical Technology Co.,\u202fLtd. announced today that the New Drug Application (NDA) for MK\u20116240\/XTR006, developed by its partner Lantheus Holdings, Inc. (NASDAQ: LNTH), has been accepted by the U.S. Food and Drug Administration (FDA). The agent is designed to detect tau neuro\u2011fibrillary tangle (NFT) pathology in patients with cognitive impairment who are being evaluated for Alzheimer\u2019s disease.","og_url":"https:\/\/flcube.com\/?p=45955","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-05T16:24:21+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0513.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45955#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45955"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sinotau Receives FDA NDA Approval for MK\u20116240 Tau PET Imaging Agent","datePublished":"2025-11-05T16:24:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45955"},"wordCount":291,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45955#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0513.webp","keywords":["Lantheus","Market approval filings","NASDAQ: LNTH","Sinotau Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45955#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45955","url":"https:\/\/flcube.com\/?p=45955","name":"Sinotau Receives FDA NDA Approval for MK\u20116240 Tau PET Imaging Agent - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45955#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45955#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0513.webp","datePublished":"2025-11-05T16:24:21+00:00","description":"Beijing Sinotau International Pharmaceutical Technology Co.,\u202fLtd. announced today that the New Drug Application (NDA) for MK\u20116240\/XTR006, developed by its partner Lantheus Holdings, Inc. (NASDAQ: LNTH), has been accepted by the U.S. Food and Drug Administration (FDA). The agent is designed to detect tau neuro\u2011fibrillary tangle (NFT) pathology in patients with cognitive impairment who are being evaluated for Alzheimer\u2019s disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45955#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45955"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45955#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0513.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0513.webp","width":1080,"height":608,"caption":"Sinotau Receives FDA NDA Approval for MK\u20116240 Tau PET Imaging Agent"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45955#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sinotau Receives FDA NDA Approval for MK\u20116240 Tau PET Imaging Agent"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0513.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45955"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45955\/revisions"}],"predecessor-version":[{"id":45959,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45955\/revisions\/45959"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45958"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}